Stanley N. Cohen, M.D.
Professor, Departments of Genetics and Medicine,
Principal Investigator, The Stanley N. Cohen Lab
Stanford University

Dr. Cohen’s studies on bacterial plasmid-based antibiotic resistance led to the invention, (together with Dr. Herbert Boyer), of recombinant DNA methodology in 1973. This seminal discovery was the cornerstone in the birth of "genetic engineering" and was the foundation for the creation of industrial biotechnology. Today, he continues to study mechanisms that lead to the pathogenesis of infectious diseases and the evolution and dissemination of microbial drug resistance, as well as to work at elucidating the signals that govern RNA decay in bacteria and growth control in mammalian cells. Dr. Cohen’s honors and awards include the National Medal of Science, the National Medal of Technology, the Albert Lasker Basic Medical Research Award, the Shaw Prize in Life Science and Medicine, and the Albany Prize in Biomedical Sciences. Dr. Cohen has been a member of FivePrime’s Scientific Advisory Board since January 2003.

Joseph L. Goldstein, M.D.
Professor and Chairman, Department of Molecular Genetics
University of Texas Southwest Medical School

Dr. Joseph Goldstein and his colleague Dr. Michael S. Brown have worked together for the last 30 years on the genetics and regulation of cholesterol metabolism. Their discovery of the LDL receptor as the major molecule regulating cholesterol metabolism and its genetic disruption in the human disease familial hypercholesterolemia has been recognized by numerous awards, including the Albert D. Lasker Award in Basic Medical Research (1985), the Nobel Prize in Physiology or Medicine (1985), and the U.S. National Medal of Science (1988). More recently, Drs. Goldstein and Brown's discovery of the SREBP family of membrane-bound transcription factors and the elucidation of the proteolytic pathway by which the SREBPs become activated to regulate lipid metabolism was recognized by the receipt of the Albany Medical Prize in Biomedical Sciences in 2003. Dr. Goldstein has been a member of FivePrime’s Scientific Advisory Board since July 2002.

C. Ronald Kahn, M.D.

C. Ronald Kahn, M.D. is the preeminent investigator of insulin signal transduction and mechanisms of altered signaling in disease. He received his education at the University of Louisville and Washington University. He worked at the National Institutes of Health where he rose to Head of the Section on Cellular and Molecular Physiology of NIDDK. In 1981, he became Research Director of the Joslin Diabetes Center, and in 1986 the Mary K. Iacocca Professor of Medicine at Harvard Medical School. From 2000-2007, he served as President and Director of the Joslin Diabetes Center. He currently serves as Head of the Section on Integrative Physiology and Metabolism at the Joslin Diabetes Center. Dr. Kahn has been a member of Five Prime’s Scientific Advisory Board since July 2004.

Robert J. Lefkowitz, M.D.
Howard Hughes Medical Institute Investigator
James B. Duke Professor of Medicine
Duke University Medical Center

Dr. Robert J. Lefkowitz has spent his entire research career working on the molecular and regulatory properties of the G protein coupled receptor super family, the largest family of cell surface receptors and the commonest target for therapeutic drugs. Using the beta2-adrenergic receptor and related receptors as his models he discovered their universal molecular and regulatory properties such as their seven transmembrane spanning architecture and desensitization by G protein coupled receptor kinases and beta-arrestins. For his discoveries he has been recognized by numerous awards including the Gairdner Foundation International Award, the Shaw Prize in Life Science and Medicine, the Institut de France Fondation Lefoulon-Delalande Grand Prix for Science Award, the Jesse Stevenson Kovalenko Medal from the National Academy of Sciences, the Albany Medical Prize in Medicine & Biomedical Research and the United States National Medal of Science. Dr. Lefkowitz has been a member of Five Prime’s Scientific Advisory Board since October 2002.

Ronald Levy, M.D.
Professor of Medicine and Chief, Division of Oncology
Stanford University School of Medicine

Dr. Ronald Levy’s landmark research on the basic immuno-biology of lymphocytes and on monoclonal antibodies led to the development of rituximab, a widely successful treatment for B-cell lymphoma. Dr. Levy continues to study the mechanism of lymphoma initiation and progression to develop new monoclonal and vaccine therapies for this disease. Dr. Levy has received numerous honors and awards, including the Damashek Prize from the American Society of Hematology in 2004, the Jeffrey A. Gottlieb Memorial Award from the M.D. Anderson Cancer Center in 2003, the Evelyn Hoffman Memorial Award from the Lymphoma Research Foundation of America in 2001 and the Medal of Honor from the American Cancer Society in 2000. He is also a member of the National Academy of Science and the National Academy of Medicine. Dr. Levy has been a member of Five Prime’s Scientific Advisory Board since October 2002.

Daniel D. Von Hoff, M.D.
Physician in Chief and Director of Translational Research
Translational Genomics Research Institute (TGen), Phoenix, Arizona

Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the initial development of many oncology agents now used routinely, including mitoxantrone, fludarabine, paclitaxel, gemcitabine, irinotecan and others. At present, he is concentrating on the development of molecularly targeted therapies. Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in June 2004. He also currently serves as Chief Scientific Officer for US Oncology and Chief Scientific Officer, Scottsdale Clinical Research Institute. Dr. Von Hoff is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, a member and past board member of the American Society of Clinical Oncology and a founder of ILEX™ Oncology, Inc. He was recently awarded the 2010 David A. Karnofsky medal from the American Society of Clinical Oncology for his outstanding clinical research impacting the lives of patients with cancer. Dr. Von Hoff has been a member of Five Prime’s Scientific Advisory Board since August 2008.

Arthur Weiss, M.D. Ph.D.
Professor of Medicine and Chief, Division of Rheumatology
UCSF

Dr. Arthur Weiss is one of the world’s leaders in the study of the signal transduction events that control lymphocyte responses. His particular interest is in signal transduction events controlled by tyrosine kinases and phosphatases how abnormalities in these mechanisms can lead to autoimmune diseases. Dr. Weiss is a Howard Hughes Medical Institute Investigator and is the Ephraim P. Engleman Distinguished Professor of Rheumatology. His other honors include the Distinguished Investigator Award from the American College of Rheumatology (2004), the Arthritis Foundation's Lee C. Howley Prize, and the American Association of Immunologists Meritorious Career Award. He is a member of the American Academy of Arts and Sciences, the Institute of Medicine and the National Academy of Sciences. Dr. Weiss has been a member of Five Prime’s Scientific Advisory Board since May 2004.

Lewis T. “Rusty” Williams, M.D.